title: Effects of brucine on bone metabolism in multiple myeloma.
abstract: The aim of this study was to explore the effects of brucine on bone metabolism in multiple myeloma (MM) and to compare brucine and bortezomib regarding the effects on MM in vitro. The half maximal inhibitory concentration (IC50) values of brucine and bortezomib in the MM cell line U266 were detected by MTT assay. In addition, the expression of alkaline phosphatase (ALP), osteocalcin (OC), osteoprotegerin (OPG) and osteoprotegerin ligand (also termed receptor activator of nuclear factor κB ligand) (RANKL) at mRNA levels were measured by RT-PCR. IC50 of bortezomib in the U266 cell line at 48 h was 22.4 nmol/l, and that of brucine was 0.16 nmol/l. Compared with osteoblasts incubated with MM cell supernatant alone, the mRNA levels of ALP, OC and OPG in osteoblasts co-treated with brucine and MM cell supernatant were higher (p<0.05), while the mRNA expression of RANKL was lower, and the ranges of the changes were all larger than those of the group treated with bortezomib (P<0.05). Brucine exerts effects on bone metabolism in multiple myeloma through the regulation of osteoclasts by osteoblasts.
authors.affiliation: Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, PR China. mayanpingcn@163.com
authors.forename: Yanping
authors.initials: Y
authors.lastname: Ma
authors.forename: Jianping
authors.initials: J
authors.lastname: Zhao
authors.forename: Yihua
authors.initials: Y
authors.lastname: Wang
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Feng
authors.forename: Hua
authors.initials: H
authors.lastname: Ren
mesh_terms: D000469:Alkaline Phosphatase / Q000235:genetics / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols; D017209:Apoptosis; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D003470:Culture Media / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D009101:Multiple Myeloma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism; D010010:Osteoclasts / Q000378:metabolism / Q000473:pathology; D053244:Osteoprotegerin / Q000235:genetics / Q000378:metabolism; D016133:Polymerase Chain Reaction / Q000379:methods; D011719:Pyrazines / Q000494:pharmacology; D053245:RANK Ligand / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D013234:Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D013331:Strychnine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D001897:Boronic Acids; D003470:Culture Media; D053244:Osteoprotegerin; D011719:Pyrazines; D053245:RANK Ligand; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C505688:TNFSF11 protein, human; D015675:Osteocalcin; D000069286:Bortezomib; C083806:brucine; D000469:Alkaline Phosphatase; D013331:Strychnine